Healthsonix Inc. DL-,001
und fundamental??????????????????????
...könnte!!..aber auch nur heisse Luft geblasen werden...
HealthSonix Inc. (OTC: HSXI) has been rated "Outperform" with a target price of $4.22 by Beacon Equity Senior Research Analyst, Shailesh Dhuri, CFA.
Anyone interested in receiving alerts regarding HealthSonix Inc. research should email members@beaconequityresearch.com with "HSXI" in the subject line.
In the report, Mr. Dhuri writes, "The Company has also developed a novel treatment method that combines sound pressure waves with low impact exercises in warm water pools to treat arthritis patients. The treatment, called AquaSonix Therapy, helps to reduce and, in some cases, eliminate arthritis pain and restore flexibility. AquaSonix Therapy, claimed to be a breakthrough in the relevant field of medical treatments, is undergoing additional clinical research trials to provide clinical evidence for expanded medical claims.
"Given the projected high growth in patient base, huge market size in the U.S. and definitive advantages enjoyed by the products and services offered by the Company, HealthSonix appears to have a favorable market environment, required to build a successful business upon."
Beacon Equity Research Disclosure
The management and analysts contributing to this report do not currently hold any shares of HealthSonix Inc. (HSXI), though they may make open market purchases after this report has been issued. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Research has been directly compensated eighteen thousand dollars directly from HealthSonix Inc. for an enrollment in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.